Answers are grounded in this paper and cite their sources.
Retrospective analysis reveals relapse linked to age, obesity, and WBC levels in B-ALL, suggesting improved therapies are needed.
Introduction: Blinatumomab (Blina) is a CD19/CD3 bispecific T-cell engager with demonstrated efficacy in B-cell acute lymphoblastic leukemia (B-ALL). It is now a part of the standard of care frontline treatment of newly diagnosed (ND) Philadelphia chromosome-negative (Ph-neg) B-ALL in combination with multiagent chemotherapy in the consolidation phase. There are very limited data on the outcomes of patients (pts) who relapse after frontline treatment with Blina-based regimens. Methods: Retrospective study including pts with ND Ph-neg B-ALL who received Blina in the frontline setting as a part of the multiagent HCVAD/HCMAD (Intensive chemotherapy; IC) or mini-HCVD (low intensity therapy; LIT) regimen in the induction, consolidation, or maintenance phase. Relapse was defined by the presence of >5% blasts in the bone marrow (BM) or extra-medullary involvement. Hazard of relapse was assessed through univariate and multivariate analysis via a competing risk regression model (death in remission as competing risk). Results: 239 pts received frontline Blina-based chemotherapy from 8/2013 - 5/2025. Composite complete response (CRc=CR+CRi) was attained in 236 pts (99%). For these responders, the median age at diagnosis was 43.5 years (range 18.3 - 87.7), and 69 pts (29%) had age≥ 60 years. 111 pts (47%) were obese (BMI>30 Kg/m2) at baseline. Median white blood cell (WBC) count (x 109/L) was 5.1 (0.2 - 553), with WBC>50k in 33 pts (14%), while median BM blasts were 84% (1 - 99), with BM blasts >50% in 197/230 pts (86%). Low hypodiploid/near triploid (HoTr) karyotype, CRLF2 overexpression (CRLF2 high), and KMT2A rearrangement (KMT2Ar) occurred in 11%, 19% and 5% pts, respectively, while TP53 mutations were noted in 25% of pts. Frontline regimens were IC in 135 pts (57%) and LIT in 101 pts (43%). Median time from diagnosis to Blina initiation was 2.8 months (mos) (0.1 – 38.6). Inotuzumab (Ino) was used frontline in 173 pts (73%). 54 pts (23%) underwent ASCT in 1st remission. After a median follow up of 37.2 mos from Blina initiation, 28 pts (12%) relapsed, and 36 pts (15%) died in remission. The 3-year cumulative incidence of relapse (CIR) was 13% (95% CI: 9% - 19%). On univariate analysis, age (p=0.06), obesity (p<0.01), WBC>50k (p=0.02), BM blasts>50% (p=0.04), and TP53 mut (p=0.08) were identified as potential risk factors for relapse. Notably, HoTr karyotype (p=0.12), KMT2Ar (p=0.17), CRLF2-high (p=0.34), chemo intensity; IC vs LIT (p=0.68), and use of frontline Ino (p=0.60) were not significantly associated with relapse risk. On multivariate analysis, age (HR 1.02, 95% CI: 1.003 - 1.05, p=0.02), obesity (HR 3.7, 95% CI: 2.5 - 5.2, p<0.01), and WBC>50k (HR 3.4, 95% CI: 2.4 - 4.8, p<0.01) were independently associated with increased risk of relapse. For the full relapsed cohort (n=28), the median age at initial diagnosis was 56 years (22 – 74), with age≥60 years in 12 pts (43%). The median time to relapse from the 1st dose of Blina was 6.1 mos (range 1.8 - 53.8). Relapse site was bone marrow (BM) alone in 10 pts (36%), extramedullary disease (EMD) alone in 9 pts (32%), and BM + EMD in 9 pts (32%). The most common EMD sites were lymph node/soft tissue in 9 pts (32%), and central nervous system (CNS) in 8 pts (29%). CNS only relapse occurred in 5 pts (18%). At relapse, loss of CD19 expression occurred in 3/25 pts (12%) with available testing. A total of 27 pts (96%) received at least one line of salvage therapy, with 2nd CRc attained in 18 pts (67%). 1st salvage regimens included chemotherapy backbone (+/- venetoclax, Blina/Ino) in 24 pts (89%), CAR-T in 2 pts, and Ino alone in 1 pt. Among those in 2nd CRc, 12/18 pts (67%) received subsequent consolidation with CAR-T and/or ASCT. After a median follow-up of 25.1 mos, median overall survival (OS) for the full relapsed cohort from the date of relapse was 8.6 mos (95% CI: 4.3 - 17.5), with 2-year OS 30%. The median OS for pts with age <60 and ≥60 years was 9.5 mos and 3.6 mos, respectively. The median OS from the date of relapse for pts who received CAR-T and/or ASCT as a consolidation in 2nd CRc was not reached (5-year OS 51%). Conclusions: Relapse after frontline Blina-based regimens in Ph-neg B-ALL is infrequent, with a 3-year CIR of 13% in our cohort. We identified older age, obesity, and baseline WBC>50k as key risk factors for relapse. Post-relapse outcomes are dismal, with a median OS of only 8.6 mos (2-year OS 30%), underscoring the need for newer therapies.
No takes yet. Share an insight, caveat, or question.
Arora et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: